Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

NMRANeumora Therapeutics, Inc.

Nasdaq · CIK 0001885522
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2836 Biological Products, (No Diagnostic Substances)
FY end1231
XBRL facts208

Identity from submissions API

NameNeumora Therapeutics, Inc.
CIK0001885522
TickersNMRA
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2836 Biological Products, (No Diagnostic Substances)
EIN844367680
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(857) 760-0900
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
260 ARSENAL PLACE, SUITE 1
WATERTOWN
MA
02472
MA
Mailing address
260 ARSENAL PLACE, SUITE 1
WATERTOWN
MA
02472
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

261 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-463633 005-94162 261561699 34 6974
2026-11-16 10-Q 10-Q 0001193125-26-462194 001-41802 261555606 34 10595169 1 1
2026-11-16 8-K 8-K 2.02,9.01 0001193125-26-462165 001-41802 261555556 34 355359 1 1
2026-10-30 8-K 8-K 3.01 0001193125-26-441634 001-41802 261508015 34 139199 1 1
2026-08-21 4 FORM 4 0001610717-26-000385 32359
2026-08-21 4 FORM 4 0001610717-26-000384 5788
2026-08-21 4 FORM 4 0001610717-26-000383 5798
2026-08-21 4 FORM 4 0001610717-26-000382 5796
2026-08-21 4 FORM 4 0001610717-26-000381 5735
2026-08-21 144 xsl144X01/primary_doc.xml 0001964306-26-000408 001-41802 261305179 33 6922
2026-08-20 144 xsl144X01/primary_doc.xml 0001964306-26-000403 001-41802 261300170 33 6283
2026-08-19 4 FORM 4 0001610717-26-000362 57618
2026-08-19 144 xsl144X01/primary_doc.xml 0001964306-26-000401 001-41802 261295428 33 5641
2026-08-18 144 xsl144X01/primary_doc.xml 0001964306-26-000400 001-41802 261291326 33 5001
2026-08-17 144 xsl144X01/primary_doc.xml 0001964306-26-000398 001-41802 261287683 33 5633
2026-08-14 10-Q 10-Q 0001193125-26-350370 001-41802 261276057 34 9817042 1 1
2026-08-14 8-K 8-K 2.02,5.02,9.01 0001193125-26-350349 001-41802 261276032 34 345443 1 1
2026-07-27 8-K 8-K 8.01,9.01 0001193125-26-316819 001-41802 261202804 34 248928 1 1
2026-06-15 8-K 8-K 1.01,2.03,2.05,7.01,8.01,9.01 0001193125-26-270328 001-41802 261089123 34 185957 1 1
2026-05-29 4 xslF345X06/form4.xml 0001610717-26-000174 5351
2026-05-29 4 xslF345X06/form4.xml 0001610717-26-000173 5339
2026-05-29 4 xslF345X06/form4.xml 0001610717-26-000171 5346
2026-05-29 4 xslF345X06/form4.xml 0001610717-26-000170 5337
2026-05-29 4 xslF345X06/form4.xml 0001610717-26-000169 5322
2026-05-29 8-K 8-K 5.07 0001193125-26-248244 001-41802 261044292 34 150238 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000905148-26-002417 005-94162 26989791 34 11329
2026-05-07 10-Q 10-Q 0001193125-26-211825 001-41802 26952961 34 8786163 1 1
2026-05-07 8-K 8-K 2.02,9.01 0001193125-26-210310 001-41802 26950825 34 283804 1 1
2026-05-04 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002005369-26-000023 005-94162 26936530 34 18650
2026-04-17 DEFA14A DEFA14A 0001193125-26-161519 001-41802 26871549 34 819307
2026-04-17 DEF 14A DEF 14A 0001193125-26-161489 001-41802 26871490 34 3966909 1 1
2026-04-01 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001012975-26-000294 005-94162 26828225 34 35645
2026-03-30 S-8 S-8 0001193125-26-130407 333-294723 26809964 33 445560 1 1
2026-03-30 10-K 10-K 0001193125-26-130388 001-41802 26809946 34 13730047 1 1
2026-03-30 8-K 8-K 2.02,9.01 0001193125-26-130372 001-41802 26809923 34 362202 1 1
2026-02-19 4 xslF345X05/form4.xml 0001610717-26-000054 4674
2026-02-19 4 xslF345X05/form4.xml 0001610717-26-000053 5387
2026-02-19 4 xslF345X05/form4.xml 0001610717-26-000052 7663
2026-02-19 4 xslF345X05/form4.xml 0001610717-26-000051 4872
2026-02-19 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002005369-26-000014 005-94162 26655070 34 25087
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-26-000895 005-94162 26642673 34 11432
2026-02-17 144 xsl144X01/primary_doc.xml 0001964306-26-000112 001-41802 26641996 33 4396
2026-02-17 144 xsl144X01/primary_doc.xml 0001964306-26-000111 001-41802 26641958 33 4394
2026-02-17 144 xsl144X01/primary_doc.xml 0001964306-26-000110 001-41802 26641864 33 4417
2026-02-17 144 xsl144X01/primary_doc.xml 0001964306-26-000109 001-41802 26641815 33 4524
2026-02-11 8-K 8-K 7.01,9.01 0001193125-26-045526 001-41802 26618325 34 6674671 1 1
2026-01-12 8-K 8-K 7.01,9.01 0001193125-26-009727 001-41802 26524615 34 5195612 1 1
2026-01-09 4 xslF345X05/form4.xml 0001610717-26-000014 5499
2026-01-09 4 xslF345X05/form4.xml 0001610717-26-000011 5519
2026-01-09 4 xslF345X05/form4.xml 0001610717-26-000010 5497
2026-01-09 4 xslF345X05/form4.xml 0001610717-26-000009 5428
2026-01-09 4 xslF345X05/form4.xml 0001610717-26-000008 5554
2026-01-05 8-K 8-K 8.01,9.01 0001193125-26-001472 001-41802 26503859 34 196477 1 1
2025-11-21 8-K 8-K 3.02,9.01 0001193125-25-291352 001-41802 251507916 34 140014 1 1
2025-11-13 4 xslF345X05/form4.xml 0001610717-25-000378 6012
2025-11-12 144 xsl144X01/primary_doc.xml 0001628280-25-051788 001-41802 251474962 33 4600
2025-11-06 10-Q 10-Q 0001193125-25-269446 001-41802 251458093 34 15730132 1 1
2025-11-06 8-K 8-K 2.02,9.01 0001193125-25-268046 001-41802 251456095 34 369097 1 1
2025-10-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-25-000681 11907
2025-10-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-25-000680 21270
2025-10-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001012975-25-000679 27718
2025-10-29 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001012975-25-000675 005-94162 251431600 34 36025
2025-10-27 8-K 8-K 8.01,9.01 0001193125-25-250677 001-41802 251417431 34 209003 1 1
2025-10-27 8-K 8-K 8.01,9.01 0001193125-25-250656 001-41802 251417368 34 212062 1 1
2025-08-11 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-002815 005-94162 251202746 34 16868
2025-08-06 10-Q 10-Q 0000950170-25-104138 001-41802 251190150 34 16335047 1 1
2025-08-06 8-K 8-K 2.02,9.01 0000950170-25-103997 001-41802 251189534 34 396434 1 1
2025-05-30 4 4 0000950170-25-079926 26174
2025-05-30 4 4 0000950170-25-079924 12792
2025-05-30 4 4 0000950170-25-079925 18476
2025-05-30 4 4 0000950170-25-079923 14614
2025-05-30 4 4 0000950170-25-079922 39643
2025-05-30 4 4 0000950170-25-079921 14626
2025-05-30 4 4 0000950170-25-079920 21699
2025-05-30 4 4 0000950170-25-079919 18232
2025-05-30 4 4 0000950170-25-079918 14517
2025-05-30 4 4 0000950170-25-079908 34826
2025-05-30 8-K 8-K 5.07 0001193125-25-132307 001-41802 251012298 34 150082 1 1
2025-05-23 4 xslF345X05/form4.xml 0001610717-25-000128 6439
2025-05-16 DEFA14A DEFA14A 0001193125-25-121717 001-41802 25959716 34 28180
2025-05-16 8-K 8-K 3.01 0001193125-25-121714 001-41802 25959698 34 148147 1 1
2025-05-12 10-Q 10-Q 0000950170-25-069311 001-41802 25935417 34 13952560 1 1
2025-05-12 8-K 8-K 2.02,9.01 0000950170-25-069147 001-41802 25934663 34 330323 1 1
2025-05-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-001531 005-94162 25933277 34 11360
2025-04-29 DEFA14A DEFA14A 0000950170-25-060098 001-41802 25887177 34 682244
2025-04-29 DEF 14A DEF 14A 0000950170-25-060084 001-41802 25887053 34 2607507 1 1
2025-04-11 PRE 14A PRE 14A 0000950170-25-053346 001-41802 25832831 34 2579417 1 1
2025-04-11 8-K/A 8-K/A 5.02 0000950170-25-053303 001-41802 25832542 34 157467 1 1
2025-03-26 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000791 333-282460 25774972 33 1863
2025-03-12 144 xsl144X01/primary_doc.xml 0001968582-25-000180 001-41802 25732381 33 4535
2025-03-03 S-8 S-8 0001193125-25-044187 333-285507 25698785 33 256406 1 1
2025-03-03 POS AM POS AM 0001193125-25-044183 333-282460 25698729 33 445006
2025-03-03 10-K 10-K 0000950170-25-030401 001-41802 25693791 34 20603108 1 1
2025-03-03 POSASR POSASR 0001193125-25-043400 333-282460 25693756 33 515758
2025-03-03 8-K 8-K 2.02,9.01 0000950170-25-030396 001-41802 25693740 34 376486 1 1
2025-02-21 8-K/A 8-K/A 5.02 0001193125-25-031974 001-41802 25651590 34 153524 1 1
2025-02-20 4 xslF345X05/form4.xml 0001610717-25-000031 7853
2025-02-20 4 xslF345X05/form4.xml 0001610717-25-000030 5422
2025-02-20 4 xslF345X05/form4.xml 0001610717-25-000029 6181
2025-02-20 4 xslF345X05/form4.xml 0001610717-25-000028 5361
2025-02-20 4 xslF345X05/form4.xml 0001610717-25-000027 6198
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000081 001-41802 25636432 33 4396
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000080 001-41802 25636416 33 4527
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000079 001-41802 25636390 33 4508
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000078 001-41802 25636372 33 4510
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000077 001-41802 25636356 33 4431
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000076 001-41802 25636345 33 4471
2025-02-18 144 xsl144X01/primary_doc.xml 0001964306-25-000075 001-41802 25636330 33 4516
2025-02-18 4 4 0000950170-25-022323 20042
2025-02-18 4 4 0000950170-25-022327 16566
2025-02-18 4 4 0000950170-25-022322 13073
2025-02-18 4 4 0000950170-25-022320 37926
2025-02-18 4 4 0000950170-25-022326 16583
2025-02-18 4 4 0000950170-25-022321 12733
2025-02-18 4 4 0000950170-25-022317 12721
2025-02-18 4 4 0000950170-25-022325 24461
2025-02-18 4 4 0000950170-25-022319 33111
2025-02-18 4 4 0000950170-25-022316 11079
2025-02-18 4 4 0000950170-25-022318 12764
2025-02-13 8-K 8-K 5.02,7.01,9.01 0001193125-25-026156 001-41802 25621176 34 184163 1 1
2025-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-019939 005-94162 25620745 34 7061
2025-01-13 8-K 8-K 7.01,9.01 0001193125-25-004999 001-41802 25524861 34 4261351 1 1
2025-01-02 8-K 8-K 8.01,9.01 0001193125-25-000084 001-41802 25500214 34 185422 1 1
2024-12-27 4 xslF345X05/form4.xml 0001610717-24-000555 9890
2024-11-22 SC 13D/A ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D/A(#2) 0001072613-24-000899 005-94162 241491098 34 648355
2024-11-12 SC 13G formsc13g.htm 0001493152-24-044786 005-94162 241448895 34 227455
2024-11-12 10-Q 10-Q 0000950170-24-125437 001-41802 241448407 34 10407200 1 1
2024-11-12 8-K 8-K 2.02,9.01 0000950170-24-124563 001-41802 241443257 34 303227 1 1
2024-10-18 4 xslF345X05/form4.xml 0001610717-24-000511 23999
2024-10-18 144 xsl144X01/primary_doc.xml 0001964306-24-000383 001-41802 241380736 33 5088
2024-10-17 144 xsl144X01/primary_doc.xml 0001964306-24-000382 001-41802 241377879 33 4490
2024-10-11 4 xslF345X05/form4.xml 0001610717-24-000505 7083
2024-10-10 144 xsl144X01/primary_doc.xml 0001964306-24-000376 001-41802 241365551 33 7043
2024-10-09 144 xsl144X01/primary_doc.xml 0001964306-24-000375 001-41802 241362883 33 6412
2024-10-01 S-3ASR S-3ASR 0001193125-24-230348 333-282460 241344451 33 1388518
2024-09-19 4 xslF345X05/form4.xml 0001610717-24-000490 7085
2024-09-18 144 xsl144X01/primary_doc.xml 0001964306-24-000364 001-41802 241307888 33 5784
2024-09-17 144 xsl144X01/primary_doc.xml 0001964306-24-000363 001-41802 241304943 33 5151
2024-09-16 4 xslF345X05/form4.xml 0001610717-24-000478 5220
2024-09-13 4 xslF345X05/form4.xml 0001610717-24-000475 18859
2024-09-12 144 xsl144X01/primary_doc.xml 0001964306-24-000357 001-41802 241295776 33 4410
2024-08-27 4 xslF345X05/form4.xml 0001610717-24-000457 5872
2024-08-26 4 xslF345X05/form4.xml 0001610717-24-000456 9941
2024-08-22 144 xsl144X01/primary_doc.xml 0002002698-24-000259 001-41802 241230405 33 4411
2024-08-06 10-Q 10-Q 0000950170-24-091737 001-41802 241179008 34 9216496 1 1
2024-08-06 8-K 8-K 2.02,9.01 0000950170-24-091205 001-41802 241177073 34 303463 1 1
2024-07-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-24-001797 005-94162 241104907 34 11133
2024-07-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-24-001795 005-94162 241104011 34 8689
2024-06-28 4 xslF345X05/form4.xml 0001610717-24-000380 5836
2024-06-14 4 xslF345X05/form4.xml 0001610717-24-000338 7013
2024-06-14 4 xslF345X05/form4.xml 0001610717-24-000337 6998
2024-06-14 4 xslF345X05/form4.xml 0001610717-24-000336 7028
2024-06-14 4 xslF345X05/form4.xml 0001610717-24-000335 7030
2024-06-14 4 xslF345X05/form4.xml 0001610717-24-000334 14825
2024-06-14 8-K 8-K 5.07 0001193125-24-161572 001-41802 241044592 34 156501 1 1
2024-05-07 10-Q 10-Q 0000950170-24-054448 001-41802 24921653 34 9794175 1 1
2024-05-07 8-K 8-K 2.02,9.01 0000950170-24-053933 001-41802 24919592 34 256364 1 1
2024-04-25 DEFA14A DEFA14A 0000950170-24-048333 001-41802 24876484 34 262620
2024-04-25 DEF 14A DEF 14A 0000950170-24-048287 001-41802 24876176 34 1006399
2024-04-24 4 xslF345X05/form4.xml 0001610717-24-000222 5515
2024-04-15 8-K 8-K 8.01 0001193125-24-095472 001-41802 24843071 34 147333 1 1
2024-03-07 S-8 S-8 0001193125-24-062239 333-277748 24730678 33 95390
2024-03-07 10-K 10-K 0000950170-24-027927 001-41802 24730051 34 12821279 1 1
2024-03-07 8-K 8-K 2.02,9.01 0001193125-24-061473 001-41802 24728136 34 227360 1 1
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000069 7280
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000068 7331
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000067 7318
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000066 7221
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000065 9043
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000064 7404
2024-02-16 4 xslF345X05/form4.xml 0001610717-24-000063 7316
2024-02-14 SC 13G SC 13G 0001193125-24-036256 005-94162 24638580 34 46180
2024-02-13 SC 13G formsc13g.htm 0001493152-24-006168 005-94162 24627564 34 254781
2024-01-08 8-K 8-K 7.01,9.01 0001193125-24-003968 001-41802 24518502 34 10695689 1 1
2023-12-15 SC 13D/A ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D/A(#1) 0001072613-23-000627 005-94162 231491247 34 658052
2023-12-12 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-022481 22441
2023-12-12 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-022480 28790
2023-12-12 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-022479 14005
2023-12-12 4 xslF345X05/form4.xml 0001610717-23-000398 5365
2023-12-12 3 xslF345X02/form3.xml 0001610717-23-000397 10298
2023-11-28 8-K 8-K 8.01,9.01 0001193125-23-284303 001-41802 231446747 34 148604 1 1
2023-11-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-020934 8764
2023-11-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-020933 16387
2023-11-13 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-020714 14285
2023-11-13 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-020712 21908
2023-11-07 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-020280 10599
2023-11-07 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-020279 18222
2023-11-01 10-Q 10-Q 0000950170-23-057424 001-41802 231368195 34 9891737 1 1
2023-11-01 8-K 8-K 2.02,9.01 0001193125-23-268165 001-41802 231368093 34 235917 1 1
2023-10-02 SC 13D ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D 0001072613-23-000508 005-94162 231297318 34 662823
2023-09-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-018633 10599
2023-09-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-018632 18222
2023-09-27 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-018548 8760
2023-09-27 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-018547 16383
2023-09-27 SC 13D SC 13D 0001193125-23-243053 005-94162 231281818 34 113104
2023-09-25 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-018469 18223
2023-09-25 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-018468 10599
2023-09-21 4 FORM 4 SUBMISSION 0001209191-23-050240 21985
2023-09-20 4 xslF345X05/form4.xml 0001610717-23-000291 30918
2023-09-20 4 FORM 4 SUBMISSION 0000899243-23-019274 41084
2023-09-20 4 FORM 4 SUBMISSION 0000899243-23-019273 45036
2023-09-20 S-8 S-8 0001193125-23-237903 333-274593 231265202 33 477752
2023-09-19 4 xslF345X05/form4.xml 0001610717-23-000290 6586
2023-09-19 4 xslF345X05/form4.xml 0001610717-23-000289 10296
2023-09-19 8-K 8-K 5.03,8.01,9.01 0001193125-23-237644 001-41802 231263999 34 438391 1 1
2023-09-18 4 xslF345X05/form4.xml 0001610717-23-000286 7133
2023-09-18 4 xslF345X05/form4.xml 0001610717-23-000285 5203
2023-09-18 4 xslF345X05/form4.xml 0001610717-23-000284 5218
2023-09-18 4 xslF345X05/form4.xml 0001610717-23-000283 5234
2023-09-18 4 xslF345X05/form4.xml 0001610717-23-000282 5144
2023-09-18 4 xslF345X05/form4.xml 0001610717-23-000281 5127
2023-09-18 424B4 424B4 0001193125-23-236920 333-274229 231261315 33 3770836
2023-09-18 3 FORM 3 SUBMISSION 0000899243-23-019226 13460
2023-09-14 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2023-09-14 16:00:00 9999999995-23-002676 333-274229 231260019 33 1809
2023-09-14 SEC STAFF LETTER filename1.pdf 9999999997-23-004194 63737
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019101 43784
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019099 47745
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019093 21405
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019084 8064
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019082 13408
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019081 8138
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019080 8043
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019079 9692
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019078 14738
2023-09-14 3 FORM 3 SUBMISSION 0001209191-23-049494 10829
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019074 12986
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019071 6175
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019070 11407
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019068 11908
2023-09-14 3 FORM 3 SUBMISSION 0000899243-23-019063 15979
2023-09-14 CERT 8A_cert_NMRA.pdf 0001354457-23-000670 001-41802 231254771 34 183981
2023-09-13 8-A12B 8-A12B 0001193125-23-234448 001-41802 231253317 34 14650
2023-09-12 CORRESP filename1.htm 0001193125-23-233465 7682
2023-09-12 CORRESP filename1.htm 0001193125-23-233460 8829
2023-09-11 S-1/A S-1/A 0001193125-23-231902 333-274229 231246590 33 5255187
2023-08-25 CORRESP filename1.htm 0001193125-23-221597 39260
2023-08-25 S-1 S-1 0001193125-23-221589 333-274229 231209169 33 8034745
2023-08-17 UPLOAD filename1.pdf 0000000000-23-009015 43954
2023-08-09 DRS/A filename1.htm 0000950123-23-006927 377-05663 231153157 33 4098117
2023-08-08 DRSLTR filename1.htm 0000950123-23-006930 37480
2023-07-12 UPLOAD filename1.pdf 0000000000-23-007447 45532
2023-06-30 DRSLTR filename1.htm 0000950123-23-005917 41932
2023-06-30 DRS/A filename1.htm 0000950123-23-005916 377-05663 231062495 33 4624820
2023-05-24 SEC STAFF LETTER filename1.pdf 9999999997-23-002978 64898
2023-05-24 UPLOAD filename1.pdf 0000000000-23-005549 52885
2023-05-02 DRS/A filename1.htm 0000950123-23-003601 377-05663 23880485 33 3302946
2023-01-03 D xslFormDX01/primary_doc.xml 06b 0001567619-23-000019 021-469477 23501653 33 12129
2022-09-02 DRSLTR filename1.htm 0000950123-22-009779 29792
2022-09-02 DRS/A filename1.htm 0000950123-22-009778 377-05663 221226165 33 4769569
2022-06-17 UPLOAD filename1.pdf 0000000000-22-006617 43993
2022-06-10 DRSLTR filename1.htm 0000950123-22-006852 33424
2022-06-10 DRS/A filename1.htm 0000950123-22-006850 377-05663 221009931 33 4743066
2022-05-16 UPLOAD filename1.pdf 0000000000-22-005312 48026
2022-05-02 DRS/A filename1.htm 0000950123-22-004443 377-05663 22882861 33 4464638
2022-02-14 DRS/A filename1.htm 0000950123-22-002276 377-05663 22624314 33 5441045
2022-02-11 DRSLTR filename1.htm 0000950123-22-002278 26877
2022-01-07 UPLOAD filename1.pdf 0000000000-22-000215 44164
2021-12-23 DRS/A filename1.htm 0000950123-21-016457 377-05663 211514185 33 4533664
2021-12-22 DRSLTR filename1.htm 0000950123-21-016461 57752
2021-12-06 UPLOAD filename1.pdf 0000000000-21-014636 61135
2021-11-08 DRS filename1.htm 0000950123-21-014224 377-05663 211388837 33 3713114

Latest XBRL company facts

One latest value per concept from companyfacts (208 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 188.69M 2026-11-11 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
dei EntityPublicFloat Entity Public Float USD 63.30M 2025-06-30 2025 FY 10-K 2026-03-30 0001193125-26-130388
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 407,407 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161489
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 5.02M 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161489
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 10.5 2025-01-01 2025-12-31 DEF 14A 2026-04-17 0001193125-26-161489
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.95M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AccretionExpense Accretion Expense USD 791,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 20.97M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 991,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 187,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 62,000 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.33B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD 6.14M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 20.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AmortizationOfFinancingCosts Amortization of Debt Issuance Costs USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 410,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 39.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap Assets Assets USD 95.05M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AssetsCurrent Assets, Current USD 94.75M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 290.66M 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedGain Debt Securities, Available-for-sale, Unrealized Gain USD 70,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Debt Securities, Available-for-sale, Unrealized Loss USD 8,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 239.79M 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054448
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 290.72M 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 44,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 85.65M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 85.65M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -96.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 57.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 700.00M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 174.26M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 174.26M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CommonStockValue Common Stock, Value, Issued USD 19,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -130.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 843.69M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD 130,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 130,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 58.17M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap DebtInstrumentFeeAmount Debt Instrument, Fee Amount USD 4.20M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD 1.00M 2025-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-269446
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredFederalStateAndLocalTaxExpenseBenefit Deferred Federal, State and Local, Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 105,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 330.29M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 87.21M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 105,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 164.69M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 358,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 35.43M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 9.39M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 330.18M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 0 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 800,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.03 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent pure 0.5 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap Depreciation Depreciation USD 200,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 18,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.71 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.71 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.217 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.029 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.001 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.018 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.027 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 7.24M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD -559,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap GainLossOnInvestments Gain (Loss) on Investments USD 18,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 71,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-350370
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 37.97M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 600,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -130.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 31,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 31,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncomeTaxPaidFederalAfterRefundReceived IncomeTaxPaidFederalAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxPaidForeignAfterRefundReceived IncomeTaxPaidForeignAfterRefundReceived USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 51.13M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -49.73M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 4.38M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 45,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationPriorYearIncomeTaxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount USD 350,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 80,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 6.42M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -1.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -7.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -210,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncreaseDecreaseInOtherOperatingCapitalNet Increase (Decrease) in Other Operating Assets and Liabilities, Net USD -2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap InterestExpense Interest Expense USD 4.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap InterestExpenseDebt Interest Expense, Debt USD 5.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 5.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 2.17M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-350370
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 3.67M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-350370
us-gaap InvestmentIncomeAmortizationOfDiscount Investment Income, Amortization of Discount USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 2.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap InvestmentIncomeNet Investment Income, Net USD 10.96M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-01 0000950170-23-057424
us-gaap InvestmentIncomeNetAmortizationOfDiscountAndPremium Investment Income, Net, Amortization of Discount and Premium USD 3.07M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-01 0000950170-23-057424
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 1.89M 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 1.89M 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 1.89M 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 39,000 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap Liabilities Liabilities USD 76.50M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 95.05M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LiabilitiesCurrent Liabilities, Current USD 23.19M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebt Long-term Debt USD 53.30M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 60.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 58.17M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 53.30M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 165.43M 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 9.85M 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap NetAssetValuePerShare Net Asset Value Per Share USD/shares 1 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 22.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -119.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -130.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -2.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OperatingExpenses Operating Expenses USD 128.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -128.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 5.23M 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 267,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OperatingLeasePayments Operating Lease, Payments USD 3.72M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 234,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.1 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 697,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 66,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OtherNoncashExpense Other Noncash Expense USD 6,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -23,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 44,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 3.83M 2024-06-30 2024 Q2 10-Q 2024-08-06 0000950170-24-091737
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 1.63M 2024-06-30 2024 Q2 10-Q 2024-08-06 0000950170-24-091737
us-gaap PaymentsForRent Payments for Rent USD 3.70M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 445,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 200,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PaymentsToAcquireInProcessResearchAndDevelopment Payments to Acquire in Process Research and Development USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 50.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap PreferredStockValueOutstanding Preferred Stock, Value, Outstanding USD 0 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 9.09M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 232.56M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 810,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 112.22M 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap ProceedsFromLongTermLinesOfCredit Proceeds from Long-term Lines of Credit USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 36.58M 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054448
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 517,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 239,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 1.61M 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -130.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 227,000 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 25,000 2026-06-30 2026 Q2 10-Q 2026-08-14 0001193125-26-350370
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 90.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap RestrictedCash Restricted Cash USD 0 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-211825
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 147.07M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001193125-26-211825
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 1.21M 2024-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 0 2024-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -1.32B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 20.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.959 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.876 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.05 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 300,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 18.55M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.127 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125437
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 598,000 2024-04-01 2024-06-30 2024 Q2 10-Q 2024-08-06 0000950170-24-091737
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 1.99M 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 239,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 226.52M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 33,000 2024-07-01 2024-09-30 2025 Q3 10-Q 2025-11-06 0001193125-25-269446
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 517,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 843.69M 2022-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 856.76M 2022-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 50.00M 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap UnamortizedDebtIssuanceExpense Unamortized Debt Issuance Expense USD 1.83M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 10.04M 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 358,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 97,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027927
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 65.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388
us-gaap VariableLeaseCost Variable Lease, Cost USD 100,000 2022-01-01 2022-12-31 2024 FY 10-K 2025-03-03 0000950170-25-030401
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 184.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 184.32M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-462194
us-gaap WriteOffOfDeferredDebtIssuanceCost Write off of Deferred Debt Issuance Cost USD 447,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-30 0001193125-26-130388

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →